Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARMAC: Standard Chemotherapy in Triple Negative Breast Cancer
NCT04771871Phase 2Recruiting
- Sponsor
- University College Hospital, Ibadan
- Start
- Nov 2021
- Primary completion
- Mar 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of epirubicin, cyclophosphamide, paclitaxel, carboplatin in triple-negative breast cancer (TNBC), sponsored by University College Hospital, Ibadan. Started Nov 2021; status: recruiting.
02
Drugs
epirubicincyclophosphamidepaclitaxelcarboplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04771871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04771871.